Table 4.
Release of APIs from formulations with (CG)4TBA (1) or (CG)4TOA (2) into serum, as measured after 24 h.
| Hybrid | API | Molar ratio: API/hybrid | Amount of API in preparation [nmol] | Medium[a] | API release after 24 h [nmol] (% of API) |
|---|---|---|---|---|---|
| 1 | daunomycin | 8:1 | 400 | FBS | 35 (9) |
| 1 | doxorubicin | 12:1 | 620 | FBS | 26 (4) |
| 1 | epirubicin | 12:1 | 117 | FBS[b] | 10 (9) |
| 1 | proflavine | 10:1 | 100 | FBS[b] | 24 (24) |
| 1 | mitoxantrone | 5:1 | 50 | FBS[b] | 10 (20) |
| 1 | imatinib | 8:1 | 84 69 | H2O FBS | 15 (18) 55 (79) |
| 1 | tetracycline | 5:1 | 38 | H2O | 15 (40) |
| 1 | streptomycin | – | – | H2O | n.d.[c] |
| 1 | methotrexate | 1.2:1 | 180 | H2O[d] | 35 (20) |
| 1 | gramicidin A | 0.5:1 | 5 | H2O[e] | 5 (quant.) |
| 1 | cyclosporin A | 1:1 | 10 | H2O[e] | 10 (quant.) |
| 2 | doxorubicin | 13:1 | 130 | FBS | 19 (15) |
| 2 [f] | doxorubicin | 11:1 | 110 | FBS | 22 (20) |
| 2 | imatinib | 20:1 | 120 | FBS | 82 (68) |
| 2 [f] | imatinib | 6:1 | 60 | FBS | 60 (quant.) |
[a] Treated with 100 μL medium at 37 °C for 1 d, unless otherwise noted. [b] Treated with 200 μL. [c] Solid was treated with H2O at 50 °C; streptomycin was detected by TLC. [d] Solid was treated at 50 °C for 15 min. [e] Solid was treated with 200 μL at 70 °C for 10 min and stored at 37 °C for 1 d, after which time it had dissolved quantitatively. [f] Inclusion compound had been prepared at a mixing temperature of 37 °C. All other inclusion compounds had been prepared at a mixing temperature of 70 °C.